Access the full text.
Sign up today, get DeepDyve free for 14 days.
T. Yaguchi, Y. Goto, K. Kido, H. Mochimaru, T. Sakurai, N. Tsukamoto, C. Kudo-Saito, T. Fujita, H. Sumimoto, Y. Kawakami (2012)
Immune Suppression and Resistance Mediated by Constitutive Activation of Wnt/β-Catenin Signaling in Human Melanoma CellsThe Journal of Immunology, 189
P. Tumeh, C. Harview, J. Yearley, I. Shintaku, E. Taylor, L. Robert, B. Chmielowski, M. Spasić, G. Henry, V. Ciobanu, Alisha West, M. Carmona, C. Kivork, E. Seja, Grace Cherry, Antonio Gutierrez, T. Grogan, C. Mateus, G. Tomasic, J. Glaspy, R. Emerson, H. Robins, R. Pierce, D. Elashoff, C. Robert, A. Ribas (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 515
J. Sosman, Kevin Kim, L. Schuchter, R. Gonzalez, A. Pavlick, J. Weber, G. McArthur, Thomas Hutson, S. Moschos, K. Flaherty, P. Hersey, R. Kefford, D. Lawrence, I. Puzanov, K. Lewis, R. Amaravadi, B. Chmielowski, H. Lawrence, Y. Shyr, Fei Ye, Jiang Li, K. Nolop, Richard Lee, A. Joe, A. Ribas (2012)
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.The New England journal of medicine, 366 8
J. Marin-Acevedo, B. Dholaria, A. Soyano, K. Knutson, S. Chumsri, Y. Lou (2018)
Next generation of immune checkpoint therapy in cancer: new developments and challengesJournal of Hematology & Oncology, 11
Mareike Grees, Adi Sharbi-Yunger, C. Evangelou, Daniel Baumann, G. Cafri, E. Tzehoval, S. Eichmüller, R. Offringa, J. Utikal, L. Eisenbach, V. Umansky (2018)
Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma modelsOncoImmunology, 7
D. Knight, S. Ngiow, Ming Li, Tiffany Parmenter, Stephen Mok, Ashley Cass, N. Haynes, K. Kinross, H. Yagita, R. Koya, T. Graeber, A. Ribas, G. McArthur, M. Smyth (2013)
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.The Journal of clinical investigation, 123 3
V. Volpe, Daniel Klufas, U. Hegde, J. Grant-Kels (2017)
The new paradigm of systemic therapies for metastatic melanomaJournal of the American Academy of Dermatology, 77
C. Robert, B. Karaszewska, J. Schachter, P. Rutkowski, A. Mackiewicz, D. Stroiakovski, M. Lichinitser, R. Dummer, F. Grange, L. Mortier, V. Chiarion-Sileni, K. Drucis, I. Krajsová, A. Hauschild, P. Lorigan, P. Wolter, G. Long, K. Flaherty, P. Nathan, A. Ribas, Anne-Marie Martin, P. Sun, W. Crist, J. Legos, S. Rubin, S. Little, D. Schadendorf (2015)
Improved overall survival in melanoma with combined dabrafenib and trametinib.The New England journal of medicine, 372 1
J. Khalili, Shujuan Liu, Tania Rodríguez-Cruz, Mayra Whittington, S. Wardell, Chengwen Liu, Minying Zhang, Z. Cooper, Dennie Frederick, Yufeng Li, Min Zhang, R. Joseph, C. Bernatchez, S. Ekmekcioglu, E. Grimm, L. Radvanyi, R. Davis, M. Davies, J. Wargo, P. Hwu, G. Lizée (2012)
Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in MelanomaClinical Cancer Research, 18
G. Long, J. Grob, P. Nathan, A. Ribas, C. Robert, D. Schadendorf, S. Lane, Carmen Mak, P. Legenne, K. Flaherty, M. Davies (2016)
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.The Lancet. Oncology, 17 12
Ruma Pengal, Latha Ganesan, G. Wei, Huiqing Fang, Michael Ostrowski, S. Tridandapani (2006)
Lipopolysaccharide-induced production of interleukin-10 is promoted by the serine/threonine kinase Akt.Molecular immunology, 43 10
Dennie Frederick, A. Piris, Alexandria Cogdill, Z. Cooper, C. Lezcano, Cristina Ferrone, D. Mitra, Andrea Boni, Lindsay Newton, Chengwen Liu, W. Peng, R. Sullivan, D. Lawrence, F. Hodi, W. Overwijk, G. Lizée, G. Murphy, P. Hwu, K. Flaherty, D. Fisher, J. Wargo (2013)
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic MelanomaClinical Cancer Research, 19
Hao Luo, Masayo Umebayashi, Keiko Doi, T. Morisaki, S. Shirasawa, T. Tsunoda (2016)
Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells.Anticancer research, 36 7
H. Sumimoto, Fumie Imabayashi, T. Iwata, Y. Kawakami (2006)
The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cellsThe Journal of Experimental Medicine, 203
Michael Martin, R. Schifferle, N. Cuesta, S. Vogel, J. Katz, S. Michalek (2003)
Role of the Phosphatidylinositol 3 Kinase-Akt Pathway in the Regulation of IL-10 and IL-12 by Porphyromonas gingivalis Lipopolysaccharide1The Journal of Immunology, 171
H. Davies, G. Bignell, Charles Cox, P. Stephens, S. Edkins, S. Clegg, J. Teague, H. Woffendin, Mathew Garnett, W. Bottomley, Neil Davis, E. Dicks, Rebecca Ewing, Yvonne Floyd, K. Gray, S. Hall, R. Hawes, Jaime Hughes, Vivian Kosmidou, A. Menzies, Catherine Mould, A. Parker, C. Stevens, S. Watt, S. Hooper, Rebecca Wilson, H. Jayatilake, B. Gusterson, C. Cooper, J. Shipley, D. Hargrave, K. Pritchard-Jones, N. Maitland, G. Chenevix-Trench, G. Riggins, D. Bigner, G. Palmieri, A. Cossu, A. Flanagan, A. Nicholson, Judy Ho, Suet Leung, S. Yuen, Barbara Weber, H. Seigler, T. Darrow, H. Paterson, R. Marais, Christopher Marshall, R. Wooster, Michael Stratton, P. Futreal (2002)
Mutations of the BRAF gene in human cancerNature, 417
T. Inozume, T. Yaguchi, Junpei Furuta, K. Harada, Y. Kawakami, S. Shimada (2016)
Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.The Journal of investigative dermatology, 136 1
M. Tucci, S. Stucci, A. Passarelli, G. Giudice, F. Dammacco, F. Silvestris (2014)
The immune escape in melanoma: role of the impaired dendritic cell functionExpert Review of Clinical Immunology, 10
Serine/threonine‐protein kinase B‐Raf (BRAF) inhibitors are very effective in treating melanoma with BRAF mutations. BRAF inhibitors suppress aberrant growth of melanoma cells caused by BRAF mutations. BRAF mutations reportedly result in melanoma cells releasing immunosuppressive factors, and BRAF inhibitors elicit anti‐melanoma immune responses by reducing such factors. However, immunological characteristics of tumor cells that acquire resistance to BRAF inhibitors remain unknown. Here, we compared immunological characteristics between a melanoma cell line and its vemurafenib‐resistant subline. No differences were observed in the status of BRAF mutations, expression of surface molecules related to antitumor T‐cell responses or recognition by human leukocyte antigen‐A*0201‐matched melanoma‐specific cytotoxic T lymphocytes in a short‐term co‐culture assay. However, resistant tumor cells released high amounts of interleukin‐10 depending on aberrant activation of Akt signaling, and dendritic cell functions were considerably suppressed by culture supernatants of the resistant cells. Our findings demonstrated a novel immunological mechanism contributing to tumor growth owing to drug resistance to BRAF inhibitors.
The Journal of Dermatology – Wiley
Published: Dec 1, 2018
Keywords: ; ; ; ;
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.